The Latest Cardiac and Vascular News
Allegheny Health Network’s (AHN) Allegheny Valley Hospital (AVH) has completed a $12 million expansion and renovation of its imaging and radiology department. The new 8,000-square-foot imaging center, located on the ground floor of AVH, offers state-of-the-art imaging technologies and…
Harrison.rad.1 significantly outperforms other major models on radiology tasks The new model is being made accessible to select healthcare professionals and regulators to open up the conversation on responsible use of AI in healthcare SYDNEY, Sept. 4, 2024 /PRNewswire/ — Healthcare AI…
Niagara Falls, NY, Aug. 26, 2024 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce the sale of Positron’s NeuSight PET-CT 64 slice scanner to a recognized leader in preventive, invasive and interventional cardiovascular services.
WOBURN, Mass., Aug. 5, 2024 /PRNewswire/ — Sirtex Medical (“Sirtex”), a leading manufacturer of interventional treatment solutions, announced today the launch of its SIR-Spheres® FLEXdose SELECT Delivery Program, an innovative, new way to offer precise Y-90 selective internal radiation therapy for the treatment of metastatic colorectal cancer. SIR-Spheres® FLEXdose SELECT Delivery Program offers unparalleled flexibility by […]
BURLINGAME, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — Attralus, Inc., a clinical stage biopharmaceutical company developing transformative products to improve the lives of patients with systemic amyloidosis, today announced that its investigational diagnostic imaging agent drug, 124I-evuzamitide (AT-01), has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for positron emission tomography (PET) imaging in patients with suspected or known cardiac amyloidosis. FDA granted BTD for 124I-evuzamitide (AT-01) based on clinical data from Attralus-sponsored and investigator-initiated studies evaluating the use of 124I-evuzamitide in patients with cardiac amyloidosis, representing experience in more than 200 trial participants.
SEOUL, South Korea, July 30, 2024 /PRNewswire/ — SwiftMR™, the artificial intelligence (AI) solution for magnetic resonance imaging (MRI) from AIRS Medical, has been approved for use in Canada. Hospitals, radiology centers, and other diagnostic imaging facilities across the country can…
Powerful generative AI software will enhance diagnostic speed, precision & patient outcomes Powerful generative AI software will enhance diagnostic speed, precision & patient outcomes
MIAMI, July 25, 2024 /PRNewswire/ — AbbaDox, a leading provider of cloud-based healthcare solutions, is pleased to announce a strategic relationship with Merge Healthcare Solutions to deliver an enhanced suite of radiology workflow solutions. Merge ambulatory radiology workflow solutions…
BILLERICA, Mass.–(BUSINESS WIRE)–Access Vascular, Inc. (AVI), a medical device company dedicated to reducing and eliminating common and costly vascular access complications with its novel MIMIX® catheter material, announced today that it is preparing to submit its HydroGUIDE™ catheter placement technology for U.S. Food & Drug Administration (FDA) clearance. “Combining the innovative […]
Agreement to acquire business adds innovative, real-time image recognition technology and expertise to GE HealthCare’s portfolio of AI-enabled devices AI-based technology from Intelligent Ultrasound aims to provide real-time support for OBGYN scans and improve exam accuracy and efficiency Planned acquisition supports GE HealthCare’s precision care strategy to address inefficiencies and […]
